72.11.Z - Research and experimental development on biotechnology
21.10.Z - Manufacture of basic pharmaceutical substances
21.20.Z - Manufacture of medicines and other pharmaceutical products
46.46.Z - Wholesale of pharmaceutical goods
70.22.Z - Business and other management consultancy activities
72.19.Z - Other research and experimental development on natural sciences and engineering
74.90.Z - Other professional, scientific and technical activities not elsewhere classified
82.99.Z - Other business support service activities not elsewhere classified
86.90.E - Other human health activities notelsewhere classified
2021 | 2022 | 2023 | ||
---|---|---|---|---|
M PLN | M PLN | M PLN | % | |
Profit (loss) on sale | 11,1 | 1,5 | -1,7 | -215,7 |
Gross profit (loss) | 11 | 2 | -1,9 | -195,2 |
EBITDA | 11,3 | 1,7 | -1,5 | -188,5 |
Short time liabilities | 11,3 | 14,9 | 13,3 | -10,8 |
Other operating costs | 0 | 0 | 0 | 1794,3 |
Equity capital | 7,6 | 7,3 | 5,4 | -26,3 |
Operating profit (EBIT) | 11,1 | 1,5 | -1,5 | -203,3 |
Assets | 21,4 | 28,1 | 44,2 | 57,3 |
Net profit (loss) | 10,1 | 1,6 | -1,9 | -217 |
Cash | 3 | 12,9 | 1,2 | -90,6 |
Net income from sale | 43,3 | 22,2 | 0 | -100 |
Liabilities and provisions for liabilities | 13,8 | 20,8 | 38,8 | 86,7 |
Working assets | 16,4 | 14,3 | 1,6 | -89,1 |
Other income costs | 0 | 0 | 0,2 | 7230,6 |
Depreciation | 0,2 | 0,2 | 0 | -82,9 |
% | % | % | p.p. | |
Profitability of capital | 133 | 22,4 | -35,6 | -58 |
Equity capital to total assets | 35,4 | 26 | 12,2 | -13,8 |
Gross profit margin | 25,4 | 9,1 | -56 339,5 | -56 348,6 |
EBITDA Margin | 26,2 | 7,7 | -44 434,7 | -44 442,4 |
Days | Days | Days | Days | |
Short term commitment turnover cycle | 95 | 245 | 1 420 554 | 1 420 309 |
Current financial liquidity indicator | 1.4475377798080444 | 0.9604727625846863 | 0.11741061508655548 | -0,9 |
Net dept to EBITDA | -0.2615034282207489 | -7.213253498077393 | -5.462584018707275 | 1,7 |
Opinie dotyczące usług, produktów oraz działalności firmy nie są weryfikowane